Cormorant Asset Management
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles.
Business Model:
Revenue: $27.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Cormorant Asset Management Information
Geographic Data
Address:
City: Chagrin Falls
State: OH
Zip: 44022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$253M
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace. Cormorant Asset Management was founded in 2013 and is based in Boston, Massachusetts, United States.
Contact Phone:
+14402473200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2017 | Tricida | Series D | 0 |
| 12/2015 | X4 Pharmaceuticals | Series A | 37.5M |
| 12/2018 | Atia Vision | Series C | 10M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 6/2018 | Cibus | Series C | 70M |
| 2/2018 | Avrobio | Series B | 60M |
| 4/2018 | Supira Medical | Series A | 15.5M |
| 6/2015 | Kezar Life Sciences | Series A | 23M |
| 11/2020 | Ambrx | Private Equity Round | 200M |
| 12/2018 | Erasca | Series A | 42M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 8/2020 | Tango Therapeutics | Venture Round | 50M |
| 9/2020 | Adona Medical | Series A | 0 |
| 4/2022 | Adona Medical | Series B | 0 |
| 10/2021 | ShouTi | Series B | 0 |
| 6/2019 | Viela Bio | Series B | 0 |
| 1/2016 | Twist Bioscience | Series D | 61M |
| 2/2021 | Ensoma | Series A | 0 |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 11/2017 | X4 Pharmaceuticals | Series B | 27M |
| 10/2017 | InflaRx | Series D | 55M |
| 5/2020 | Atea | Series D | 215M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 2/2019 | NuVera Medical | Series B | 15M |
| 9/2020 | Galecto | Series D | 0 |
| 7/2015 | AnaptysBio | Series D | 40M |
| 10/2020 | Longboard Pharmaceuticals | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 4/2021 | GH Research | Series B | 125M |
| 3/2020 | Element Science | Series C | 145.6M |
| 2/2019 | Neurogene | Series A | 68.5M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 6/2020 | Greenlight Biosciences | Series D | 102M |
| 8/2022 | JenaValve Technology | Series C | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 1/2016 | Scholar Rock | Series B | 36M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 7/2020 | Praxis Precision Medicines | Series C | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 12/2020 | RayzeBio | Series B | 105M |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 3/2020 | Akouos | Series B | 105M |
| 6/2021 | Stablix | Series A | 63M |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 8/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 3/2017 | 908 Devices | Series D | 20M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 9/2020 | BioShin | Series A | 60M |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 5/2021 | Jenscare Biotech | Venture Round | - |
| 7/2020 | BioAtla | Series D | 0 |
| 4/2020 | Tango Therapeutics | Series B | 60M |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 6/2023 | Myra Vision | Series B | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 4/2015 | MyoKardia | Series B | 0 |
| 2/2015 | Advaxis | Post-IPO Equity | 0 |
| 1/2022 | ONK Therapeutics | Series A | 21.5M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 12/2015 | Gelesis | Private Equity Round | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 4/2017 | NuVera Medical | Series A | 11M |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 3/2021 | DTx Pharma | Series B | 100M |
| 11/2022 | FogPharma | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2017 | Autolus | Series C | 80M |
| 1/2022 | Akura Medical | Series A | 25M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 12/2021 | connectRN | Venture Round | 0 |
| 7/2021 | Prime Medicine | Series B | 200M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 3/2016 | ImmuneXcite | Series A | 8.6M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 12/2017 | Bigfoot Biomedical | Series B | 0 |
| 12/2015 | Axonics Modulation Technologies | Series B | 0 |
| 5/2021 | Elpiscience Biopharmaceuticals | Series C | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 1/2020 | Bigfoot Biomedical | Series C | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 6/2021 | Myra Vision | Series A | 17M |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2022 | Atia Vision | Series E | 0 |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 1/2016 | C4 Therapeutics | Series A | 73M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 8/2018 | Renovia | Series B | 32.3M |
| 3/2016 | Quanterix | Series D | 46M |
| 3/2020 | Supira Medical | Series B | 0 |
| 7/2017 | Axonics Modulation Technologies | Series C | 20.5M |
| 3/2021 | Neurelis | Series D | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 5/2019 | Atia Vision | Series D | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 2/2022 | Supira Medical | Series C | 0 |
| 10/2016 | Bigfoot Biomedical | Series A | 0 |
| 2/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 5/2021 | BiVACOR | Series B | 19M |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 115M |
| 1/2021 | FogPharma | Series C | 107M |
| 4/2023 | BioVentrix | Series A | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 3/2021 | EpimAb Biotherapeutics | Series C | 0 |
| 1/2018 | Scholar Rock | Series C | 47M |
| 5/2017 | Axonics Modulation Technologies | Series C | 0 |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 9/2017 | Replimune Group | Series B | 55M |
| 4/2020 | Erasca | Series B | 0 |
| 9/2018 | Atreca | Series C | 125M |
| 6/2021 | Myra Vision | Series A | 17M |
| 11/2020 | Pharvaris | Series C | 80M |
| 8/2017 | Atreca | Series B | 35M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 3/2021 | Chemomab | Post-IPO Equity | 45.5M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 7/2020 | Olema Oncology | Series B | 54M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 9/2020 | Novellus | Series C | 57M |
| 10/2022 | Orionis Biosciences | Series C | 55M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 8/2020 | Freenome | Series C | 270M |
| 6/2021 | Umoja Biopharma | Series B | 0 |
| 2/2020 | ALX Oncology | Series C | 105M |
| 3/2018 | Bigfoot Biomedical | Series B | 0 |
| 7/2021 | Tioga Medical | Series B | 0 |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 6/2023 | Myra Vision | Series B | 0 |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 4/2023 | BioVentrix | Series A | 0 |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
